AIgnostics
A NEW ERA OF PATHOLOGY - Providing AI-powered precision diagnostics for pathology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | $34.0m | Series B | |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Aignostics, founded in 2018 within the Berlin Institute of Health, specializes in computational pathology, leveraging AI models trained with clinical-grade data from leading international institutes. The company serves pharmaceutical companies, clinical trial organizations, and developers of companion diagnostics (CDx). Operating in the healthcare and biotechnology market, Aignostics employs a business model centered on providing advanced pathology solutions that enhance drug development and clinical trial accuracy. Revenue is generated through service contracts, partnerships, and licensing agreements. The interdisciplinary team includes machine learners, data scientists, pathologists, biologists, software engineers, and regulatory experts, ensuring a comprehensive approach to solving complex medical challenges.
Keywords: computational pathology, AI models, pharmaceutical research, clinical trials, CDx development, healthcare, biotechnology, drug development, interdisciplinary team, Berlin Institute of Health, service contracts.